Adeno-associated virus antibody profiles in newborns, children, and adolescents
R Calcedo, H Morizono, L Wang… - Clinical and Vaccine …, 2011 - Am Soc Microbiol
Clinical and Vaccine Immunology, 2011•Am Soc Microbiol
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous
natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV
serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb
prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then
progressively increases through childhood and adolescence.
natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV
serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb
prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then
progressively increases through childhood and adolescence.
Abstract
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.
American Society for Microbiology